KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Receivables (2016 - 2026)

Medtronic (MDT) has disclosed Receivables for 13 consecutive years, with $6.4 billion as the latest value for Q1 2026.

  • Quarterly Receivables rose 3.99% to $6.4 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.4 billion through Jan 2026, up 3.99% year-over-year, with the annual reading at $6.5 billion for FY2025, 6.32% up from the prior year.
  • Receivables hit $6.4 billion in Q1 2026 for Medtronic, roughly flat from $6.4 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $6.5 billion in Q2 2025 to a low of $5.3 billion in Q3 2022.
  • Historically, Receivables has averaged $6.0 billion across 5 years, with a median of $6.0 billion in 2023.
  • Biggest five-year swings in Receivables: dropped 2.26% in 2022 and later increased 9.38% in 2023.
  • Year by year, Receivables stood at $5.6 billion in 2022, then rose by 5.47% to $5.9 billion in 2023, then grew by 5.49% to $6.3 billion in 2024, then rose by 2.06% to $6.4 billion in 2025, then fell by 0.47% to $6.4 billion in 2026.
  • Business Quant data shows Receivables for MDT at $6.4 billion in Q1 2026, $6.4 billion in Q4 2025, and $6.3 billion in Q3 2025.